ImmuneRegen BioSciences'(R) Reports Efficacy of a New Adjuvant of a Preventive Cancer Vaccine

SCOTTSDALE, AZ, Dec 21 (MARKET WIRE) --
ImmuneRegen BioSciences Inc.(R), a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), today announced that treatment
with sar9, met(O2)11 Substance P, the active component of Homspera(R),
revealed a positive adjuvant effect during a preventive study for
melanoma vaccine in mice. The positive results include reduced tumor
growth and improved mouse survival compared to administration of vaccine
alone. The latest findings seem to indicate the adjuvant potential of
Homspera, and extend to the cancer vaccine space in addition to
previously shown efficacy of Homspera in infectious disease models such
as influenza.

The study was performed at the University of Pittsburgh under the guidance
of Dr. Adriana Larregina, Associate Professor of Dermatology and
Immunology, at the University of Pittsburgh School of Medicine using
commercially available reagents from Bachem and Sigma. These results
encourage future experimentation for therapeutic studies in mice. The
demonstrated adjuvant effect, including the reduction in tumor growth, as
well as other indicators of enhanced immune system activity against the
vaccine's antigen, suggest Homspera could be an effective adjuvant with
cancer vaccines. Since the completion of the studies Dr. Larregina has
joined ImmuneRegen's Scientific Advisory Board and Bachem has agreed to
provide GMP-grade Homspera (sarSP) to ImmuneRegen for future studies.

ImmuneRegen's Chief Scientific Officer, Hal Siegel, Ph.D., noted "We have
previously shown a wide range of activity for Homspera, from human
hematopoietic stem cell activation and maturation, to acceleration of
wound healing, stand-alone treatment of pandemic influenza infection and
vaccine adjuvant activity. A common thread in our studies is the
stimulation of immune cell function. On reviewing the published study
results from Dr. Larregina's lab, as well as other findings, we are
enthused about the potential for Homspera having a positive therapeutic
effect in mice as well as in future human trials, and the Company is now
focused on aggressively moving forward to complete the preclinical
research needed to prepare for human studies."

About ImmuneRegen BioSciences, Inc.

ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences
Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company
focused on the research, development and licensing of Homspera(R).
Homspera is an adult stem cell active compound that in study results has
been shown to regenerate and strengthen the immune system and enhance
wound healing. Homspera is being developed for potential use against
infectious diseases as a stand-alone or combination therapy and as a
vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based
company has forged numerous study partnerships with industry and academic
leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace
Respiratory Research Institute and Virion Systems. For more information,
please visit www.immuneregen.com.

Statements about ImmuneRegen's future expectations, including statements
about the potential use and scientific results for ImmuneRegen's drug
candidates, science and technology, and all other statements in this press
release other than historical facts, are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934, and as that term is defined in
the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends
that such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when expected,
if at all, and, together with ImmuneRegen's business, are subject to
various risks and uncertainties. ImmuneRegen's actual results could
differ materially from expected results as a result of a number of
factors, including the uncertainties inherent in research and development
collaborations, pre-clinical and clinical trials and product development
programs (including, but not limited to the fact that future results or
research and development efforts may prove less encouraging than current
results or cause side effects not observed in current pre-clinical
trials), the evaluation of potential opportunities, the level of
corporate expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic report
on Form 10-KSB for the year ended December 31, 2008 as filed with the
Securities and Exchange Commission. There are no guarantees that any of
ImmuneRegen's proposed products will prove to be commercially successful.
ImmuneRegen undertakes no duty to update forward-looking statements.

Contact:
Michael K. Wilhelm
OR
John Fermanis
ImmuneRegen BioSciences Inc.
Phone: 480-922-3926
Email: Email Contact
Email: Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-